An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years
Phase of Trial: Phase III
Latest Information Update: 31 May 2018
Price : $35 *
At a glance
- Drugs Influenza A vaccine H5N1-Baxter (Primary)
- Indications Influenza A virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Baxter Corporation
- 22 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 13 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.